Diabetes is a chronic disease caused due to insufficient production or inappropriate use of insulin in the body. It is a collection of diseases characterized by elevated blood glucose level. It is mainly of three types – Type 1, Type 2 and gestational diabetes. Type 1 is caused by an autoimmune reaction, due to lack of insulin; whereas, type 2 diabetes is caused due to futile use of insulin.
Proper intervention is needed for diabetes as to reduce complications, such as damage of kidney, eyes, heart and feet, and death. According to World Health Organization (WHO), globally, approximately 1.5 million deaths are caused due to diabetes in 2012.
Diabetes is treated by regular physical exercise, healthy eating and medications. Insulin therapy is used for the management of Type 1 diabetes and it is also used in some cases of Type 2 diabetes. Insulin helps body cells to use the glucose in the food taken by a person. In addition, insulin treatment is needed permanently for diabetes Type 1 patients.
Insulin delivery devices refer to the devices that are used to administer insulin to the body. The major devices used for the administration of insulin include insulin pen, insulin syringe, insulin pump, and others (jet injectors and insulin inhalers). The cartridge used in these devices is excluded from the scope of market size calculation. The increasing prevalence of diabetes, growing geriatric population, increasing prevalence of obesity, technological advancement of drug delivery devices and increasing awareness of diabetic care are driving the growth of the global insulin delivery device market.
Geographically, in 2015, North America accounted for the largest market share in the global insulin delivery device market. The increasing prevalence of diabetes is driving the growth of insulin delivery device market in North America. Diabetes has become one of the major public health problems in North America, due to increasing number of geriatric population and increasing prevalence of obesity. According to ADA in 2012, approximately 29.1 million Americans had diabetes. Similarly, according to IDF in 2015, 44.3 million people suffered from diabetes in North America and Caribbean, and the number is expected to reach 60.5 million in 2035. Therefore, the increasing number of diabetes population and growing prevalence of obesity would drive the growth of the insulin delivery devices market in North America.
Some of the other key players operating in the global insulin delivery device market include Eli Lilly and Company, Abbott Laboratories, Sanofi S.A., Insulet Corporation, Dickinson and Company, Becton, Animas Corporation, F. Hoffmann-La Roche Ltd., Ypsomed Holdings AG and B. Braun Melsungen AG.